Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108004 · ClinicalTrials.gov registry record · Phase 3
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00108004 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 400 participants.
The verdict
NCT00108004, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.
Interventions
- DRUG pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108004
The ClinicalTrials.gov registry entry for NCT00108004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pramlintide acetate is the first listed.
NCT00108004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108004 about?
NCT00108004 is a clinical study titled "Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus". This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.
What is the current status of trial NCT00108004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2003-04. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00108004?
The interventions under investigation include: pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00108004?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.